Keyphrases
Transplant Recipients
100%
Capecitabine
100%
Non-melanoma Skin Cancer
100%
Solid Organ Transplant Recipients
100%
Squamous Cell Carcinoma (SqCC)
28%
Incidence Rate
28%
Tumor Development
28%
Immunosuppression
14%
Randomized Trial
14%
Renal Function
14%
5-fluorouracil (5-FU)
14%
Prodrug
14%
Adjuvant Therapy
14%
High Incidence
14%
Wilcoxon Signed-rank Test
14%
Mean Reduction
14%
Nausea
14%
Actinic Keratosis
14%
Dose Adjustment
14%
Laboratory Monitoring
14%
Toxicity Monitoring
14%
Gout
14%
Case Series Design
14%
Skin Toxicity
14%
Skin Screening
14%
Days of Treatment
14%
Treatment Cycle
14%
Pharmacology, Toxicology and Pharmaceutical Science
Skin Carcinoma
100%
Capecitabine
100%
Non Melanoma Skin Cancer
66%
Side Effect
50%
Squamous Cell Carcinoma
33%
Neoplasm
33%
Prodrug
16%
Syndrome
16%
Nausea
16%
Gout
16%
Actinic Keratosis
16%
Adjuvant
16%
Fluorouracil
16%
Isoprenaline
16%